DK0521842T3 - Tumorantigenspecifikt antistof - Google Patents

Tumorantigenspecifikt antistof

Info

Publication number
DK0521842T3
DK0521842T3 DK92850166T DK92850166T DK0521842T3 DK 0521842 T3 DK0521842 T3 DK 0521842T3 DK 92850166 T DK92850166 T DK 92850166T DK 92850166 T DK92850166 T DK 92850166T DK 0521842 T3 DK0521842 T3 DK 0521842T3
Authority
DK
Denmark
Prior art keywords
antibody
specific antibody
tumor antigen
antigen
culturing
Prior art date
Application number
DK92850166T
Other languages
English (en)
Inventor
Leif Lindholm
Jan Holmgren
Peter Lind
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Application granted granted Critical
Publication of DK0521842T3 publication Critical patent/DK0521842T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
DK92850166T 1991-07-03 1992-07-03 Tumorantigenspecifikt antistof DK0521842T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9102074A SE9102074D0 (sv) 1991-07-03 1991-07-03 Tomour antigen specific antibody

Publications (1)

Publication Number Publication Date
DK0521842T3 true DK0521842T3 (da) 1999-06-14

Family

ID=20383243

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92850166T DK0521842T3 (da) 1991-07-03 1992-07-03 Tumorantigenspecifikt antistof

Country Status (19)

Country Link
US (1) US5552293A (da)
EP (1) EP0521842B1 (da)
JP (1) JP3194020B2 (da)
KR (1) KR100246681B1 (da)
AT (1) ATE171193T1 (da)
AU (2) AU658198B2 (da)
CA (1) CA2073124C (da)
DE (1) DE69226990T2 (da)
DK (1) DK0521842T3 (da)
EE (1) EE03031B1 (da)
ES (1) ES2124250T3 (da)
FI (1) FI109207B (da)
HU (2) HU218084B (da)
IE (1) IE80841B1 (da)
IL (1) IL102390A (da)
NO (1) NO315472B1 (da)
NZ (1) NZ243435A (da)
SE (1) SE9102074D0 (da)
WO (2) WO1993001302A1 (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402430L (sv) 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
ES2619313T3 (es) * 2001-03-15 2017-06-26 Precision Biologics, Inc. Terapia de anticuerpos monoclonales para el cáncer de páncreas
DE10116552A1 (de) * 2001-04-03 2002-10-10 Abc Armbruster Biochemicals Verfahren zur Bestimmung der wirksamen Parathormon-Aktivität in einer Probe
US20060246060A1 (en) * 2002-07-02 2006-11-02 Nesta Douglas P Novel stable formulation
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
CA2525130C (en) 2003-05-20 2014-04-15 Immunogen, Inc. Improved cytotoxic agents comprising new maytansinoids
AU2006213662B2 (en) 2005-02-11 2010-08-05 Immunogen, Inc. Process for preparing stable drug conjugates
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
AU2012244244B2 (en) * 2005-08-11 2015-08-27 Arpi Matossian-Rogers TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease
BRPI0614366A2 (pt) * 2005-08-11 2009-10-06 Arpi Matossian Rogers peptìdeo, anticorpo ou fragmento de anticorpo, anticorpo ou ligante funcionalmente equivalente, molécula de ácido nucleico, vetor, célula hospedeira, métodos para expressar um peptìdeo, um anticorpo ou fragmento de anticorpo, um anticorpo ou ligante equivalente e para tratar uma doença em um paciente, composição farmacêutica, composição de vacina, métodos de vacinação de um indivìduo contra uma doença ou um distúrbio e de diagnose de um indivìduo para a presença de anticorpos autoimunes, e, arranjo de peptìdeos
AU2006283726C1 (en) 2005-08-24 2015-05-07 Immunogen, Inc. Process for preparing maytansinoid antibody conjugates
ES2570731T3 (es) 2008-08-05 2016-05-20 Toray Industries Método de detección de cáncer
ES2726945T3 (es) 2009-06-03 2019-10-10 Immunogen Inc Métodos de conjugación
WO2012135517A2 (en) 2011-03-29 2012-10-04 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
ME03353B (me) 2011-03-29 2019-10-20 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
NZ707091A (en) 2012-10-04 2018-12-21 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
WO2015076425A1 (ja) * 2013-11-25 2015-05-28 リンク・ジェノミクス株式会社 新規モノクローナル抗体
MA40934A (fr) 2014-11-19 2017-09-27 Immunogen Inc Procédé de préparation de conjugués agent de liaison cellulaire-agent cytotoxique
AU2017206656B2 (en) 2016-01-10 2024-02-01 Neotx Therapeutics Ltd. Immunopotentiator enhanced superantigen mediated cancer immunotherapy
CN108601848A (zh) 2016-02-05 2018-09-28 伊缪诺金公司 用于制备细胞结合剂-细胞毒性剂缀合物的有效方法
CN107167590B (zh) * 2017-04-14 2019-03-08 江苏福隆生物技术有限公司 糖类抗原242的板式化学发光法检测试剂盒及制备方法
WO2019035034A1 (en) * 2017-08-16 2019-02-21 The Broad Institute, Inc. NEURONAL DOSAGE METHOD INVOLVING CALCINEURIN
WO2020230142A1 (en) 2019-05-15 2020-11-19 Neotx Therapeutics Ltd. Cancer treatment
AU2021357520A1 (en) 2020-03-05 2022-09-29 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752569A (en) * 1984-06-21 1988-06-21 The Regents Of The University Of California Sialylated Lewisx epitope, antibodies and diagnosis
US4904596A (en) * 1985-08-07 1990-02-27 Fred Hutchinson Cancer Research Center Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside
SE8902043L (sv) * 1988-11-10 1990-05-11 Pharmacia Ab Foerfarande foer karakterisering av makromolekyler
WO1992001474A1 (en) * 1990-07-20 1992-02-06 Kabi Pharmacia Ab Heterobifunctional reagents and conjugates with oxaalkylene units for amphiphilic bridge structures
EP0610179B1 (en) * 1990-07-20 1996-10-16 Pharmacia AB (reg.number 556131-9608) Target specific antibody-superantigen conjugates and their preparation

Also Published As

Publication number Publication date
HUT71193A (en) 1995-11-28
AU658198B2 (en) 1995-04-06
IE922188A1 (en) 1993-01-13
CA2073124C (en) 2007-06-19
ATE171193T1 (de) 1998-10-15
IL102390A0 (en) 1993-01-14
NO934777L (no) 1994-02-11
JP3194020B2 (ja) 2001-07-30
HU211512A9 (en) 1995-11-28
NZ243435A (en) 1994-10-26
FI935970A (fi) 1993-12-31
HU218084B (hu) 2000-05-28
IL102390A (en) 1996-01-19
HU9400011D0 (en) 1994-05-30
WO1993001302A1 (en) 1993-01-21
NO934777D0 (no) 1993-12-22
US5552293A (en) 1996-09-03
ES2124250T3 (es) 1999-02-01
AU2292092A (en) 1993-02-11
NO315472B1 (no) 2003-09-08
EP0521842A2 (en) 1993-01-07
FI109207B (fi) 2002-06-14
KR100246681B1 (ko) 2000-04-01
EE03031B1 (et) 1997-08-15
WO1993001303A1 (en) 1993-01-21
JPH05276987A (ja) 1993-10-26
DE69226990D1 (de) 1998-10-22
AU1942592A (en) 1993-01-07
FI935970A0 (fi) 1993-12-31
EP0521842A3 (da) 1994-01-26
EP0521842B1 (en) 1998-09-16
DE69226990T2 (de) 1999-03-25
IE80841B1 (en) 1999-03-24
SE9102074D0 (sv) 1991-07-03
CA2073124A1 (en) 1993-01-04

Similar Documents

Publication Publication Date Title
DK0521842T3 (da) Tumorantigenspecifikt antistof
FI101937B1 (fi) Menetelmä monoklonaalisen vasta-aineen tuottamiseksi, joka reagoi ihmisen cachectiinin kanssa
EP0822830A4 (en) HUMAN ANTIBODIES FROM IMMUNIZED XENOMAS
EP0584715A3 (de) Gewinnung und Kultivierung transformierter Zellen und Herstellung gegen sie gerichteter Antikörper.
DE69127487D1 (de) Verfahren zum Nachweis der Alzheimer-Krankheit
DE3684211D1 (da)
IT7920789A0 (it) Metodo e mezzo per regolare l'uniformita' dello stiramento di nastri.
FI853389L (fi) Tumoerlaekemedel och foerfarande foer dess framstaellning.
EP0218158A3 (en) Human monoclonal antibody, B-cell line for producing this antibody and method for preparing this B-cell line and antibody.
DE69015230D1 (de) Antikörper gegen menschliches Sperma, ihre Herstellung und Anwendung.
EP0166458A3 (en) Monoclonal antibody capable of specifically distinguishing human hepato-carcinoma cells
ATE243742T1 (de) Hybridzelle und deren verwendung zur herstellung eines arzneimittels zur induktion einer tumorimmunität
RU93058456A (ru) Антитела, способы диагностики, способ лечения, фармацевтическая композиция, клеточные линии
DK182188A (da) Humant tumorassocieret antigen
IT8020164A0 (it) Procedimento per produrre colture sporifere di un ceppo di clavicepspurpurea virulento sulla segale e producente l'ergocristina.